Healthcare - Press Releases

LEUVEN,Belgium and STRASBOURG, France and PHILADELPHIA, April 15, 2025 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meetingbeing held in Chicago, IL from April 25-30, 2025.

ALHAMBRA, Calif., April 15, 2025 /PRNewswire/ --Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the first quarter ended March 31, 2025, after the close of the stock market on Thursday, May 8, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day.

OVERLAND PARK,Kan., April 15, 2025 /PRNewswire/ -- Dendi, a leading cloud-native laboratory information system (LIS) provider, is excited to announce a strategic partnership with Molecular Lab Partners (MLP), a consultancy specializing in fast and efficient high-complexity lab implementations. This collaboration brings together Dendi's modern LIS platform with MLP's end-to-end consulting services to streamline the launch of physician office laboratories (POLs), urgent care centers, and multi-location lab networks.

South Dakota Health Care Professionals Choose Strong Union Representation

PORT WASHINGTON, N.Y., April 15, 2025 /PRNewswire/ -- ParkerWaichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, islinked tothe active ingredient, semaglutide, in Ozempic and Wegovy. The case is now pending in the Superior Court of New Jersey, Middlesex County.

LISSABON, Portugal, 15. April 2025 /PRNewswire/ -- Vernachlssigung ist eine der am weitesten verbreiteten und dennoch gemeinhin bersehenen Bedrohungen fr das Wohlergehen eines Kindes. Im Gegensatz zu Kindesaussetzungen bleibt Vernachlssigung oft unbemerkt und fhrt dazu, dass Kinder in einem Kreislauf aus chronischem emotionalem Schaden, verlorenem Vertrauen und langfristigen Entwicklungsproblemen gefangen sind.

With the introduction of a subcutaneous formulation, ENTYVIO has expanded patient convenience and global accessibility. Continued growth is supported by rising IBD prevalence and ongoing geographic expansion.

FORT WASHINGTON, Pa., April 15, 2025 /PRNewswire/ -- CCA Industries, Inc. (OTC: CAWW), announced today its results for the three months ended February 28, 2025 which can be found in the chart below.

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX,NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101(131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2].

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days, through SEDAR+

WASHINGTON, April 15, 2025 /PRNewswire/ -- From Washington to Brussels to the Black Sea,Qorvis advisors have been actively shaping public discourse during a critical period of geopolitical transformation. As elections redraw political maps, global institutions face mounting pressure, and new threats emerge in sectors from healthcare to shipping, Qorvis continues to offer clarity, credibility, and strategic insight to clients and global audiences alike.

Software Engineering Team Enables First-of-Its-Kind Metabolic Wearable at Fraction of Laboratory Cost

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquiredGeron securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

STUART, Fla., April 14, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the first quarter ended March 31, 2025.

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies.

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics. The drug has become the first to receive FDA approval specifically for treating immunoglobulin G4-related disease (IgG4-RD).

SHANGHAI, 14 avril 2025 /PRNewswire/ -- La 91e dition du salon China International Medical Equipment Fair (CMEF) s'est acheve le 11 avril 2025 Shanghai, et a permis de prsenter les technologies mdicales rvolutionnaires de prs de 5000exposants et d'attirer des centaines de milliers de participants venus de plus de 150pays.

REAL ID Not Required for Air Travel from May 7th

TORRANCE, Calif., April 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024.

FRANKILN, Mass., April 14, 2025 /PRNewswire/ -- Amsino has taken a significant step forward in our mission to advance healthcare worldwide. We are proud to announce the establishment of Amsino Scientific Inc., a new medical device manufacturing, research, and development facility based in Franklin, Massachusetts.

INCHEON, South Korea, April 14, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). YUFLYMAis an FDA-approved, high-concentration (100mg/mL) and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory indications.[1]

To further advance oncology with technology, the biotech startup is setting up a 3D cancer pathology lab in the Phoenix-based Discovery Oasis biotech space.

HONG KONG and SHANGHAI, April 14, 2025 /PRNewswire/ -- On April 14, the 2025 Hainan Free Trade Port Global Investment Promotion Conference was held in Haikou. Jointly hosted by the People's Government of Hainan Province and the Ministry of Commerce, the conference is one of the key events in the 2025 "Invest in China" series. With the theme "Invest in Hainan, Connect with the World," the event showcased the achievements, business environment, and investment opportunities of the Hainan Free Trade Port (FTP) to global investors. Wang Qunbin, Co-Chairman of Fosun International, delivered a speech as a representative of key enterprises.

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA;NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025.

LONDON, April 15, 2025 /PRNewswire/ -- Westbourne River Partners letter to Biotest AG with respect to the delisting offer made by Grifols SA to shareholders of Biotest.